Focusing on innovation, unveiling new vision creation.

Link to: News

News

Link to: Projects

Projects

Link to: ESG-Sustainability

ESG

News

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

The first study participant was recruited to the phase-2 myopia control trial.
Clinical trials

Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome

The first study participant was recruited to the phase-2 myopia control trial.

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

The first study participant was recruited to the phase-2 myopia control trial.

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

The first study participant was recruited to the phase-2 myopia control trial.
Stock Market2

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

Qisda Corporation Becomes a Strategic Investor in Sunhawk vision Biotech, Inc.

Qisda Corporation (Stock Symbol: 2352) will subscribe to 4,500,000 privately placed shares of our company at a price of NT$54 per share.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2024 Nobel Prize in Physiology or Medicine has been awarded for the discovery of microRNA.

本公司「視航生醫(7759)」，正是臺灣首間RNA治療藥物開發技術平台公司，致力研發核酸藥物用於治療近視、乾眼症與其他眼睛疾病，主要核心產品——miRNA-328抑制劑，用於治療近視、乾眼症與眼角膜破損，目前皆進入臨床二期或即將進入臨床三期。

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

The first study participant was recruited to the phase-2 myopia control trial.
Clinical trials

Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome

The first study participant was recruited to the phase-2 myopia control trial.

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

The first study participant was recruited to the phase-2 myopia control trial.

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

The first study participant was recruited to the phase-2 myopia control trial.
Stock Market2

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

Qisda Corporation Becomes a Strategic Investor in Sunhawk vision Biotech, Inc.

Qisda Corporation (Stock Symbol: 2352) will subscribe to 4,500,000 privately placed shares of our company at a price of NT$54 per share.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2024 Nobel Prize in Physiology or Medicine has been awarded for the discovery of microRNA.

本公司「視航生醫(7759)」，正是臺灣首間RNA治療藥物開發技術平台公司，致力研發核酸藥物用於治療近視、乾眼症與其他眼睛疾病，主要核心產品——miRNA-328抑制劑，用於治療近視、乾眼症與眼角膜破損，目前皆進入臨床二期或即將進入臨床三期。

最新消息

2022 Taipei Biotech Award.

Read more

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept